Skip to main content
. Author manuscript; available in PMC: 2019 Oct 15.
Published in final edited form as: Cancer. 2018 Sep 25;124(20):4010–4022. doi: 10.1002/cncr.31726

Table 3.

Adjusted 10-year Overall and Prostate Cancer-Specific Survival according to Tumor Stage in Men Undergoing Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy plus Androgen Deprivation Therapy

Tumor Stage Radical Prostatectomy with Adjuvant
Radiotherapy
Radiotherapy and Androgen Deprivation Therapy Difference (95% CI)
Event rate per
thousand
Adjusted
Survival(%)
Event rate per
thousand
Adjusted Survival(%)
10-year Prostate Cancer-Specific Survival
T3a-bN0-XM0 1.3 88.9 2.0 74.2 14.7(11.4,17.2)
T3a-bN1M0 2.2 75.7 3.7 58.6 17.1(−0.8,34.2)
T4N0-XM0 2.0 72.0 4.6 60.5 11.6(0.8,16.9)
T4N1M0 3.5 NA 8.0 NA NA
10-year Overall Survival
T3a-bN0-XM0 3.4 64.2 5.3 48.3 15.8(11.3,20.2)
T3a-bN1M0 5.6 44.3 6.5 40.5 3.8(−10.8,22.5)
T4N0-XM0 4.0 49.6 8.8 34.9 14.7(−0.1,30.5)
T4N1M0 7.8 NA 9.0 NA NA

Note: Covariates included age, race, year of diagnosis, marital status, comorbidity status, income quartiles, urban residence, SEER region, education quartiles, population quartiles. 95% CIS are bootstrapped. 10-year survival was not available in stage T4N1M0 men.